Spyre Therapeutics reports SKYWAY RA sub-study topline results for SPY072
Spyre Therapeutics announces topline results from the rheumatoid arthritis sub-study of the SKYWAY Phase 2 trial of SPY072.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.